Thursday, February 20, 2025


Enhancing shareholder accountability: Lessons from Japan’s corporate governance reforms



Study finds increased shareholder dissent in director elections after Japan’s Stewardship Code amendment on voluntary vote disclosure



Waseda University

The impact of voting disclosure on shareholder dissent in director elections 

image: 

The study found that the voluntary disclosure of institutional investor’s voting records led to increased shareholder dissent in director elections, particularly among domestic investors, demonstrating how transparency regulations can strengthen corporate governance.

view more 

Credit: Professor Toru Yoshikawa from Waseda University, Japan




Shareholders play a crucial role in corporate governance by voting on key decisions in the companies they invest in. To enhance transparency, regulatory bodies worldwide—such as government agencies and stock exchanges—are increasingly implementing guidelines to hold institutional investors accountable for their voting behavior and ensure they fulfill their fiduciary duties.

A study published in the journal Corporate Governance: An International Review on 22 January 2025 demonstrates that these regulations, even if non-binding, can encourage institutional investors to play a more active role and improve corporate governance. The study, conducted by Professor Toru Yoshikawa from Waseda University and Associate Professor Daisuke Uchida from Keio University, examined how institutional investors responded to the 2017 amendment to Japan’s Stewardship Code, which encouraged them to disclose their voting records.

“The regulatory change in the disclosure of voting records in 2017 encourages institutional investors to engage in corporate governance of their invested firms,” says Yoshikawa. “We were interested in how institutional investors, who are major corporate governance actors, reacted to this change, especially in the differences between domestic investors that were often perceived as passive in their corporate governance role and foreign investors that tend to be more active.”

To examine the impact of the regulatory change on shareholder voting, the researchers analyzed 7,887 voting proposals, covering 5,051 directors from 495 TOPIX 500 firms and the top 500 companies on the Tokyo Stock Exchange. Director candidates are recommended by the company’s board, and historically, domestic Japanese institutional investors often supported these nominees to maintain good relationships with the companies they invested in. However, after the disclosure rule took effect, the study found a significant increase in shareholder dissent in director elections.

This shift was especially noticeable in companies with high domestic institutional ownership, while companies with more foreign institutional investors saw little to no change in voting patterns. Moreover, shareholder dissent against board-recommended directors was strongest when directors were seen as underperforming or unqualified. “Prior studies show that foreign investors have different objectives from domestic investors, and they tend to pay greater attention to the corporate governance of their invested firms. However, our study shows that domestic investors more strongly reacted to the regulatory change on disclosure of voting records than foreign investors; domestic investors started to cast more dissenting votes on director candidates at general shareholders’ meetings,” says Yoshikawa.

The researchers explain that domestic institutional investors—such as local banks, trust banks, and insurance companies—are more likely to respond to local regulations because they rely on local regulatory bodies for legitimacy, whereas foreign institutional investors, who often adhere to international standards, are less influenced by domestic regulations. “Our theory and findings show that domestic institutional investors tend to diverge from foreign institutional investors in response to regulatory signals due to their different levels of dependence on the legitimacy conferred by regulatory bodies, even though they all fall under the same label of institutional investors. This suggests that shareholder preferences are not only heterogeneous but also mutable over time,” says Yoshikawa.

The increased accountability in shareholder voting following Japan’s disclosure rule demonstrates that regulatory reforms can improve corporate governance. The findings can serve as a blueprint for implementing regulatory measures in other countries in Asia that are transitioning to Western-style corporate governance systems.

 

***

 

Reference
Authors: 
Daisuke Uchida1 and Toru Yoshikawa2
DOI: 10.1111/corg.12640
Affiliations: (1) Faculty of Business and Commerce, Keio University, Tokyo
                      (2) School of Social Sciences, Waseda University, Tokyo

 

About Waseda University
Located in the heart of Tokyo, Waseda University is a leading private research university that has long been dedicated to academic excellence, innovative research, and civic engagement at both the local and global levels since 1882. The University has produced many changemakers in its history, including nine prime ministers and many leaders in business, science and technology, literature, sports, and film. Waseda has strong collaborations with overseas research institutions and is committed to advancing cutting-edge research and developing leaders who can contribute to the resolution of complex global social issues. The University has set a target of achieving a zero-carbon campus by 2032, which is in line with the Sustainable Development Goals (SDGs) adopted by the United Nations in 2015. 
To learn more about Waseda University, visit https://www.waseda.jp/top/en  

 

About Professor Toru Yoshikawa from Waseda University
Dr. Toru Yoshikawa began working at Waseda University’s Faculty of Social Sciences in 2023. He specializes in business administration, strategic management, corporate governance, top management teams, innovation, and international business. He obtained his PhD from York University and has previously taught at Nihon University, McMaster University, and Singapore Management University. Prior to that, he spent a number of years working in the finance industry. Dr. Yoshikawa is a member of the Academy of Management, the Academy of International Business, the Strategic Management Society, and the International Corporate Governance Society.

 

Socially dominant individuals are more confident but not necessarily more competent



People who strive for dominance, whether in personal or professional life, are more confident in their decision-making but are no more accurate in their choices than those of a low social status





University of Kent




Research from the University of Kent’s School of Psychology has found that people who strive for dominance, whether in personal or professional life, are more confident in their decision-making but are no more accurate in their choices than those of a lower social status.

 

The research, published by the journal Personality and Individual Differences, challenges the idea that confidence signals competence, a perception that often propels dominant individuals into leadership roles.

 

Led by Dr Andrew Martin, the research found that social dominance was comparable between males and females and both showed an effect of greater confidence, debunking the long-held belief that dominance-driven strategies are primarily male traits. 

 

Dr Martin said: ‘While high status within social hierarchies is often associated with socially dominant individuals, our research goes to show that there is no superiority in decision performance and why acting confidently can actually be an effective social strategy, regardless of ability. Our findings uncover how socially dominant individuals may traverse society, acquire and possibly even retain positions of social power and influence.’

 

To reach their conclusions the psychologists assessed performance from participants through three studies using a two-choice statistical learning decision- making task and a self-referential memory task.

 

The research paper ‘Confidence does not equal competence: Socially dominant individuals are more confident in their decisions without being more accurate’ is published by Personality and Individual Differences. (A.Martin; A Belotelova, University of Kent) doi: 10.1016/j.paid.2024.113037.

ARACHNOLOGY

New insights into the evolution of spiders, scorpions, and their relatives





The Hebrew University of Jerusalem





A new study challenges traditional views on arachnid evolution, suggesting that the transition from water to land occurred multiple times rather than in a single event. The research also highlights the role of whole-genome duplication in shaping key traits in spiders and scorpions, such as silk production and venom synthesis. These findings offer new insights into chelicerate phylogeny and provide a foundation for future genetic and evolutionary studies.

[Hebrew University of Jerusalem]– A new review paper  by Dr. Efrat Gavish-Regev from The National Natural History Collections at The Hebrew University of Jerusalem and Professor Prashant P. Sharma from the Department of Integrative Biology and Zoological Museum at the University of Wisconsin provides an updated perspective on the evolutionary history of chelicerates- a diverse and ecologically significant group of arthropods that includes spiders, scorpions, mites, and horseshoe crabs.

Published in the Annual Review of Entomology, the review examines how advances in molecular phylogenetics, evolutionary developmental biology, and genomic research have reshaped our understanding of chelicerate evolution. Traditionally, arachnids were considered a terrestrial monophyletic group—meaning they descended from a single colonization event of land by a terrestrial ancestor. However, recent phylogenomic studies challenge this view, indicating that horseshoe crabs are nested within the arachnids rather than forming a separate, sister lineage. This suggests that arachnids may have colonized land multiple times rather than through a single evolutionary event.

“The idea that all arachnids share a single terrestrial ancestor has been widely accepted for decades, but the latest molecular evidence and a different interposition of some homologies points to a more complex scenario,” says Dr. Gavish-Regev. “Instead of a straightforward transition from water to land, our research suggests that different arachnid groups may have independently adapted to terrestrial life at different points in their evolutionary history.”

One of the key findings of the study is the role of whole-genome duplications in chelicerate evolution. These events, which resulted in the duplication of entire genomes, have been identified in spiders and scorpions and may have contributed to the diversification of these groups by enabling the evolution of new biological functions, including silk production and venom synthesis.

“Arachnoid evolution has been shaped by a number of factors, including gene duplications that likely played a role in the development of key traits,” explains Prof. Sharma. “By combining phylogenetic research with new gene-editing tools, we are now in a position to explore these evolutionary changes in greater detail than ever before.”

The study also highlights new developments in the study of chelicerate phylogeny, including the application of advanced genomic techniques to resolve long-standing questions about interrelationships within the group. While some evolutionary relationships remain unresolved, the increasing availability of high-quality genomic data is expected to provide further clarity in the coming years.

The findings have broad implications for evolutionary biology, shedding light on the mechanisms that drive biodiversity and adaptation in arthropods. Beyond fundamental research, understanding chelicerate evolution can also have practical applications in areas such as pest management, biomedicine, and bio-inspired materials.

FEMICIDE NORMALIZED

1 in 5 older adults get infections after heart surgery, and women have a 60% higher risk


Investigators say postoperative infections may be greatly underestimated



Michigan Medicine - University of Michigan




One in five older adults gets an infection up to six months after heart surgery — with women far more likely to develop one, according to studies led by Michigan Medicine.

The two studies examined thousands of cases involving Medicare beneficiaries who underwent coronary artery bypass grafting, also known as CABG or heart bypass, or aortic valve replacement.

Women had 60% greater odds of developing postoperative infections, the three most common being urinary tract, pneumonia and sepsis.

Black patients also had higher rates of overall infection (28%) compared to white patients (19.2%).

The studies are published in The Journal of Thoracic and Cardiovascular Surgery.

“Our investigations highlight persistent disparities in outcomes for patients undergoing cardiac surgery that will require multidisciplinary efforts to correct,” said J'undra N. Pegues, M.D., M.S., first author of the study on infection disparities and a T32 research fellow in the Department of Cardiac Surgery at U-M Health.

In one of the studies, which covered hospitals across the state of Michigan, 21.2% of Medicare beneficiaries developed an infection up to six months after surgery.

Pneumonia and UTIs accounted for nearly 17% of all infections, and rates of infection varied nearly 40% across hospitals.

“Tracking infections beyond the short time horizon is important, as some hospitals are better equipped than others to prevent infections, and some patients face disproportionate challenges given social determinants of health,” Pegues said. 

Several past studies have uncovered lower rates of infection after these procedures.

The higher numbers found in the two current studies, investigators say, are likely due to the longer follow-up period of six months.

“Patients who have a heart bypass or valve replacement surgery are at risk for developing other infections that may come about over a longer period of time, such as UTIs and gastrointestinal infections,” said Donald Likosky, Ph.D., senior author of both studies and Richard and Norma Sarns Research Professor of Cardiac Surgery at U-M Medical School.

Most national registries neither track these additional infections nor conduct surveillance beyond 30 days after the procedure, says Charles Schwartz, M.D., chair of the Department of Surgery at Trinity Health Oakland and co-author on both of these studies.

“This likely results in a vast underestimation of the burden of infections following cardiac surgery,” Schwartz said.

Heart bypass and aortic valve replacement account for more than half of all cardiac surgical procedures in Michigan. Nationwide, CABG accounts more than 70% of all heart surgeries.

In one of the Michigan studies, patients receiving their operation at lower performing hospitals, with higher expected rates of infection, were more likely to be discharged to extended care or rehabilitation facilities.

“The findings highlight that patients are at risk for developing infections early and late after their cardiac surgical procedure,” said co-author of both studies Francis Pagani, M.D., Ph.D., the Otto Gago M.D. Endowed Professor in Cardiac Surgery at U-M Medical School and associate director of the Michigan Society of Thoracic and Cardiovascular Surgeons Quality Collaborative.

“Other age-related health conditions, such as diabetes, high blood pressure and cancer, may contribute to later-occurring infections identified in this study.”

Likosky’s study team notes that collaborative learning efforts between health care systems are needed to reduce disparities in patient outcomes.

Through a statewide quality improvement intervention spanning 2012 through 2017, hospitals that adopted infection prevention strategies were able to achieve lower the risk of pneumonia relative to the rest of the country.

“Our study reinforces the importance of bringing together hospitals and community stakeholders to identify and subsequently implement potentially modifiable hospital and community practices to prevent postoperative infections” said Syed Sikandar Raza, M.D., first author and integrated thoracic surgery resident at U-M Health.

Additional authors: Chiang-Hua Chang, Ph.D., Shiwei Zhou, M.D., Robert B. Hawkins, M.D., M.Sc., Michael P. Thompson, Ph.D., Thomas M. Braun, Ph.D., Geoffrey D. Barnes, M.D., M.Sc., Eric N. Hammond, Ph.D., Francis D. Pagani, M.D., Ph.D., Noah M. Barnett, and Jeremy Wolverton, M.D., all of University of Michigan, Alphonse DeLucia III, M.D., of University of Michigan Health-West, and Raed Alnajjar, M.D., of Henry Ford Hospital.

The Agency for Healthcare Research and Quality Provided study-related funding (R01HS029026).

The NHLBI supports Dr. Pegues under Award Number T32HL166113.

The Michigan Society of Thoracic and Cardiovascular Surgeons Quality Collaborative (MSTCVS-QC) and the Michigan Value Collaborative (MVC) supported this project.

Support for the MSTCVS-QC and MVC is provided by Blue Cross Blue Shield of Michigan as part of its Value Partnerships program. Although BCBSM and MSTCVS-QC work collaboratively, the opinions, beliefs, and viewpoints expressed by the author do not necessarily reflect the opinions, beliefs, and viewpoints of BCBSM or any of its employees. The content of this work is solely the responsibility of the authors and does not represent the official views of the Agency for Healthcare Research and Quality and the National Institutes of Health.

Papers cited:

“Interhospital Variability in 180-day Infections Following Cardiac Surgery,” The Journal of Thoracic and Cardiovascular SurgeryDOI: 10.1016/j.jtcvs.2025.01.006

“Disparities in 180-day Infection Rates Following Coronary Artery Bypass Grafting and Aortic Valve Replacement,” The Journal of Thoracic and Cardiovascular Surgery.  DOI: 10.1016/j.jtcvs.2024.12.033

DEI

New funding to support food security, economic resiliency



Four organizations selected by American Heart Association Social Impact Funds to fill critical resource gaps, further progress toward equitable health using $2M grant from Grubhub Community Fund



American Heart Association





DALLAS, Feb. 19, 2025 — The conditions in which we are born, live, learn, work, play and age — the social drivers of health — are better predictors of health and life expectancy than our genetic code. In communities nationwide, people living in locations just a handful of miles apart can have a dramatic difference in life expectancy.

To help level the playing field, the Grubhub Community Fund awarded the American Heart Association® Social Impact Funds a $2 million grant to support food security, technology innovation and economic resiliency in New York City and Chicago.

“We are grateful for this generous support, which will help fill a critical resource gap and help communities overcome barriers to high-quality, accessible health care, food security and economic empowerment,” said Regina Benjamin, M.D., MBA, chair of the Social Impact Funds Impact Investment Committee and 18th U.S. Surgeon General. “With support from the Grubhub Community Fund and other generous funding, American Heart Association Ventures offers a unique opportunity to turn philanthropy into action that makes a real and exponential difference in peoples’ lives.”

The American Heart Association Social Impact Funds will use this new support to help up to 12 organizations and entrepreneurs with significant efforts focused in Chicago and New York City through proprietary sourcing, investment and performance management processes. Four focused on Chicago have already been identified:

  • CareYaya, based in North Carolina, an on-demand marketplace connecting families with more than 25,000 students in pre-health programs to be caregivers for affordable, flexible in-home care access, while helping to expand the care workforce amidst a critical caregiver shortage;
  • Farm Generations Corporation, based in New York, a farmer-owned cooperative that supports farm viability, food access and regenerative agriculture through technological innovation and community building. Its flagship product, GrownBy, is a SNAP-eligible, direct-to-consumer e-commerce platform connecting growers and consumers across America;
  • Nectar, based in Chicago, a platform that drives innovation in food security by delivering food as medicine in partnership with charitable food organizations; and
  • RiseKit, based in Chicago, a software platform that empowers untapped talent to find jobs and improve their economic well-being and address social drivers of health through community-based organizations and job training programs

“At Grubhub, we are committed to creating meaningful change in the communities where we operate, with a focus on supporting our largest market, New York City, and hometown, Chicago. With the American Heart Association being equally committed as us in advancing food security, technology innovation, and economic resiliency, Grubhub is proud of this ongoing work, made possible by the Grubhub Community Fund, to support organizations advancing equitable health in New York City and Chicago,” said Brianna Morris, senior manager, community impact for Grubhub. “We are excited for the four organizations that have received financial support thus far, and we look forward to seeing how their communities are positively impacted.”

Organizations are selected for funding by the Social Impact Funds based on their promising solutions to address social drivers of health and local barriers to achieving equitable health. The Funds evaluate opportunities to identify innovative, evidence-based candidates that align with the American Heart Association's mission and demonstrate the potential for lasting community impact.

Learn more about the Social Impact Funds at heart.org/socialimpactfunds.

 Additional Resources:

###

 About the American Heart Association®

The American Heart Association is a relentless force for a world of longer, healthier lives. Dedicated to ensuring equitable health in all communities, the organization has been a leading source of health information for more than one hundred years. Supported by more than 35 million volunteers globally, we fund groundbreaking research, advocate for the public’s health, and provide critical resources to save and improve lives affected by cardiovascular disease and stroke. By driving breakthroughs and implementing proven solutions in science, policy, and care, we work tirelessly to advance health and transform lives every day. Connect with us on heart.org, Facebook, X or by calling 1-800-AHA-USA1.   

About the American Heart Association Social Impact Funds 

The American Heart Association’s Social Impact Funds, including the Bernard J. Tyson Impact Fund, channel capital to small and medium-sized organizations that know their community best and whose ideas accelerate innovation to address local community and national health challenges. With a focus on improving health equity and expanding access to capital, the Funds support accessible, high quality health care, food security and economic empowerment. Since launching in 2018, the Funds have provided $21.5 million in financial support to more than 130 local enterprises to positively impact the well-being of nearly 5 million people. Learn more about our work at heart.org/socialimpactfunds


 

All generic drugs are not equal, study finds



Generics made in India have more ‘severe adverse events’




Ohio State University




COLUMBUS, Ohio – Generic drugs manufactured in India are linked to significantly more “severe adverse events” for patients who use them than equivalent drugs produced in the United States, a new study finds.

 

These adverse events included hospitalization, disability, and in a few cases, death.  Researchers found that mature generic drugs, those that had been on the market for a relatively long time, were responsible for the finding.

 

The results show that all generic drugs are not equal, even though patients are often told that they are, said John Gray, co-author of the study and professor of operations at The Ohio State University’s Fisher College of Business.

 

“Drug manufacturing regulation, and therefore quality assurance practices, differ between emerging economies like India and advanced economies like the United States,” Gray said.

“Where generic drugs are manufactured can make a significant difference.”

 

“The FDA assures the public that all generics patterned after the same original drug should be equivalently safe and effective, however, this is not necessarily the case when it comes to generic drugs made in India,” added another co-author, George Ball, associate professor of operations and decision technologies at Indiana University’s Kelley School of Business.

 

Published recently in the journal Production and Operations Management, the research was led by In Joon Noh, who received his PhD at Ohio State and is now an assistant professor at Korea University. Other authors include Zachary Wright, who will receive his PhD from Ohio State and is now an assistant professor at Brigham Young University; and Hyunwoo Park, a former assistant professor at Ohio State, now at Seoul National University.

 

Several of the authors on this paper have worked closely with the Food and Drug Administration on federal grants and contracts, though this study was conducted completely independent of the FDA. These authors said working closely with the FDA gave them a deep appreciation for the importance of studying generic drug quality.

 

The study is significant because it is the first to be able to link a large sample of generic drugs to the actual plant where they were manufactured.  The FDA will not release that information through the Freedom of Information Act process. But Gray said Noh figured out how to use what is called the Structured Product Labeling dataset to link drugs to the factory where they were produced.

 

“Overcoming this lack of transparency of drug manufacturing location is one of the major accomplishments of our study,” Gray said.

Another key to the study is that it matched the drugs made in India to the same drugs made in the United States. The drugs had the same active ingredients, the same dosage form and the same route of administration.

 

“That means the drugs are pharmaceutically equivalent and we are comparing apples to apples,” he said.

 

The researchers matched 2,443 drugs made in the United States and in emerging economies.  Although the researchers included other countries in their analysis, 93% of generic drugs from emerging economy countries are made in India, so India data fully explained the results.

 

The researchers compared the frequency with which drugs were associated with adverse event reports for generic drugs made in India versus the matched drugs made in the United States. These adverse event reports are available in the FDA Adverse Event Reporting System (FAERS).

 

Although the FAERS includes all reported adverse events, in this study the researchers only used those with the most serious outcomes, including hospitalization, disability and death.

 

Results showed that the number of severe adverse events for generic drugs made in India was 54% higher than for equivalent matched generic drugs made in the United States. That was after taking into account a variety of other factors that could have impacted the results, including the volume of drugs sold.

 

The findings were driven by drugs that had been on the market for a longer time.

 

“In the pharmaceutical industry, the older drugs get cheaper and cheaper and the competition gets more intense to hold down costs,” Gray said. “That may result in operations and supply chain issues that can compromise drug quality.”

 

Gray emphasized that the results shouldn’t be taken as a reason to stop overseas production of generic drugs.

 

“There are good manufacturers in India, there are bad manufacturers in the U.S., and we’re not advocating for ending offshore production of drugs or bashing India in any way,” Gray said.

 

“We believe this is a regulatory oversight issue that can be improved.”

 

Gray said one key issue is that when the FDA inspects plants that make generic drugs in the United States, the inspections are unannounced.  But in overseas locations, the inspections are arranged in advance, which may allow manufacturers to hide problems and make it harder for the FDA to find those that do exist. Making all inspections unannounced could make a big difference, he said.

 

“A key recommendation we make in this study is for the FDA to make drug manufacturing location, such as the country of manufacture, and drug quality, transparent for consumers,” Ball added. “This can help create a market in which drug quality is incentivized more than it is today”